Give me the fringe/less validated options about how can I monitor progression from marginal zone to dlbcl? How might...

According to the NCCN Guidelines (2023), the standard monitoring typically involves regular clinical exams and imaging. However, there are some emerging and less validated approaches being studied:

Potential Monitoring Methods (Less Validated):

1. According to the Leukemia & Lymphoma Society's latest research updates:

• Liquid biopsy/circulating tumor DNA testing may help detect transformation earlier, though this is still investigational
• Molecular markers like MYC or BCL2 rearrangements might indicate higher transformation risk
• PET-CT SUV changes over time may help predict transformation risk

Risk Factors for Progression: The NCCN Guidelines and Lymphoma Research Foundation identify several factors that may increase transformation risk:

1. Higher-risk features:

• Elevated LDH levels
• B symptoms (fever, night sweats, weight loss)
• Multiple sites of involvement
• Advanced stage disease

1. Molecular features (less validated but studied):

• Certain genetic mutations (p53, MYD88)
• Specific chromosomal abnormalities

Important Caveats:

1. The Leukemia & Lymphoma Society emphasizes that transformation risk varies significantly between individuals and is often unpredictable
2. NCCN Guidelines stress that these risk factors are not definitive predictors

Always discuss monitoring plans with your healthcare team, as they can best determine the appropriate surveillance strategy based on your specific situation. These less validated options should be considered supplementary to standard monitoring approaches.